A multicenter experience with generic tacrolimus conversion

Transplantation

Volumn 92, Issue 6, 2011, Pages 653-657

  McDevitt Potter, Lisa M ^a   Sadaka, Basma ^b   Tichy, Eric M ^c   Rogers, Christin C ^b   Gabardi, Steven ^d,e  

^a TUFTS MEDICAL CENTER   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c YALE NEW HAVEN HOSPITAL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Generic; Immunosuppression; Pharmacotherapy; Tacrolimus

Indexed keywords

TACROLIMUS;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG DOSE TITRATION; DRUG ERUPTION; FEMALE; GRAFT RECIPIENT; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MOUTH PAIN; NAUSEA; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; VISION;

AREA UNDER CURVE; DRUG COSTS; DRUG SUBSTITUTION; DRUGS, GENERIC; FEMALE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; ORGAN TRANSPLANTATION; PROSPECTIVE STUDIES; RISK; TACROLIMUS; TREATMENT OUTCOME;

EID: 80052664899     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31822a79ad     Document Type: Article

References (23)

1. Meier-Kriesche HU, Li S, Gruessner RWG, et al. Immunosuppression: Evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6: 1111.
2. Abbreviated New Drug Application (ANDA): Generics. Center for Drug Evaluation and Research. Available at: www.fda.gov. Accessed August 15, 2010.
3. Davit BM, Nwakama PE, Buehler GJ, et al. Comparing generic and innovator drugs: A review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother 2009; 43: 1583.
4. Guidance on Tacrolimus. US Food and Drug Administration. Availableat: www.fda.gov/downloads/drugs/guidancecomplianceregulatory information/guidances/ ucm181006. Accessed August 15, 2010.
5. Bioequivalence Requirements: Critical Dose Drugs. Health Canada File #06-112871-930. Minister of Public Works and Government Services 2006.
6. Guideline on the Investigation of Bioequivalence. CPMP/EWP/QWP/1401/98 Rev. 1/Corr. European Medicines Agency. January 20, 2010.
7. SummaryMinutes of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology; April 13, 2010. US Food and Drug Administration. Available at: www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/AdvisoryCommitteeforPharma ceuticalScienceandClinicalPharmacology/UCM210930.pdf. Accessed April 20, 2010.
8. Tacrolimus. Orange book: Approved drug products with therapeutic equivalence evaluations. Available at: www.accessdata.fda.gov/scripts/cder/ob. Accessed April 10, 2011.
9. North Carolina Pharmacy Practice Act. Article 4A. 90-85.28(b1).
10. Summary results of the Sandoz tacrolimus capsules bioequivalence studies (Bioequivalent to Prografa Capsules). Sandoz Pharmaceuticals. Available at: www.340bpvp.com/public/agreements/suppliers/sandoz-tacrolimus-capsule- bioequivalency.pdf. Accessed August 15, 2010.
11. Momper JD, Ridenour TA, Schonder KS, et al. The impact of conversion fromPrograf to generic tacrolimus in liverandkidney transplant recipients with stable graft function. Am J Transplant 2011; [Epub ahead of print].
12. Guleria S, Kamboj M, Chatterjee A, et al. Generic tacrolimus (Pan Graf) in renal transplantation: An experience of 155 recipients in India. Transplant Proc 2008; 40: 2237.
13. Park K, Kim YS, Kwon KI, et al. A randomized, open-label, two-period, crossover bioavailability study of two oral formulations of tacrolimus in healthy Korean adults. Clin Ther 2007; 29: 154.
14. Kim SJ, Huh KH, Han DJ, et al. A 6-month, multicenter, single-arm pilot study to evaluate the efficacy and safety of generic tacrolimus (TacroBell) after primary renal transplantation. Transplant Proc 2009; 41: 1671.
15. Müller H, Solari S, Zuñiga C, et al. Immunosuppression with generic tacrolimus and mycophenolate mofetil in renal transplant recipients: Preliminary report in Chile. Transplant Proc 2008; 40: 705.
16. Qazi YA, Forrest KT, Venuto RC. The clinical impact of a 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function. Clin Transplant 2006; 20: 313.
17. Roza A, Tomlanovich S, Merion R, et al. Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation. Transplantation 2002; 74: 1013.
18. Taber DJ, Baillie GM, Ashcraft EE, et al. Does bioequivalence between modified cyclosporine formulations translate into equal outcomes? Transplantation 2005; 80: 1633.
19. Sabatini S, Ferguson RM, Helderman JH, et al. Drug substitution in transplantation: A National Kidney Foundation white paper.AmJ Kidney Dis 1999; 33: 389.
20. Alloway RR, Isaacs R, Lake K, et al. Report of the American Society of Transplantation Conference on immunosuppressive drugs and the use of generic immunosuppressants. Am J Transplant 2003; 3: 1211.
21. Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guidelines for the care of kidney transplant recipients. Am J Transplant 2009; 9: S17.
22. Uber PA, Ross HJ, Zuckermann AO, et al. Generic drug immunosuppression in thoracic transplantation: An ISHLT educational advisory. J Heart Lung Transplant 2009; 28: 655.
23. Average Wholesale Price. Cardinal Healthcare. Available at http://www.cardinal.com. Accessed April 1, 2010.